Ertapenem

Ertapenem (MK-0826) is a broad spectrum and long acting β-lactam antibiotic. Ertapenem has a broad-spectrum anti-anaerobic activity against a variety of anaerobes with a mode MIC of 0.12 μg/mL. Ertapenem can be used for the research of severe infections caused by bacteria in the skin, lungs, stomach, pelvis, and urinary tract[1][2].

Product Specifications

CAS Number

[153832-46-3]

Product Name Alternative

MK-0826

UNSPSC

12352005

Hazard Statement

H302-H312-H332

Target

Antibiotic; Bacterial

Type

Reference compound

Related Pathways

Anti-infection

Applications

COVID-19-immunoregulation

Field of Research

Infection; Cancer

Assay Protocol

https://www.medchemexpress.com/ertapenem.html

Solubility

10 mM in DMSO

Smiles

O=C(C(N12)=C(S[C@@H]3CN[C@H](C(NC4=CC=CC(C(O)=O)=C4)=O)C3)[C@H](C)[C@]2([H])[C@@H]([C@H](O)C)C1=O)O

Molecular Formula

C22H25N3O7S

Molecular Weight

475.51

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501

References & Citations

[1]Kenneth E Aldridge. Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes. Diagn Microbiol Infect Dis. 2002 Oct;44 (2) :181-6.|[2]C J Gill, et al. In vivo activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345) . Antimicrob Agents Chemother. 1998 Aug;42 (8) :1996-2001.

Shipping Conditions

Room temperature

Scientific Category

Reference compound1

Clinical Information

Launched

Isoform

β-lactam

Citation 01

J Antimicrob Chemother. 2023 Sep 5;78 (9) :2242-2253.|Proc Natl Acad Sci U S A. 2024 Jan 16;121 (3) :e2314514121.|Proc Natl Acad Sci U S A. 2025 Dec 2;122 (48) :e2524436122.|Adv Ther (Weinh) . 2024 Jan 12.|Biomed Res Int. 2018 Jul 2:2018:3579832.|J Antimicrob Chemother. 2020 Jul 1;75 (7) :1850-1858.|J Antimicrob Chemother. 2025 Nov 5:dkaf408.|J Clin Microbiol. 2024 May 7:e0152023.|Molecules. 2025 Mar 9;30 (6) :1224.|Nat Commun. 2021 Jul 22;12 (1) :4461.|Nat Commun. 2022 Mar 2;13 (1) :1116.